$DORM

Dorman Products, Inc. (NASDAQ:DORM) Given Average Recommendation of "Moderate Buy" by Brokerages

Dorman Products, Inc. (NASDAQ:DORM) has received an average "Moderate Buy" rating from six brokerages, with an average 12-month price target of $180.50. Recent analyst downgrades have shifted some ratings to "hold." The company's stock has a market cap of $4.01 billion, with corporate insiders owning 8.90% and institutional investors holding 84.70% of shares.

Original reporting
MarketBeat · MarketBeat
Published Feb 17, 2026, 10:19 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 17, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dorman Products, Inc. (NASDAQ:DORM) Given Average Recommendation of "Moderate Buy" by Brokerages — source image
Decision brief

The 30-second read

$DORMNeutralMed
01

Why it matters

The mixed analyst ratings reflect cautious optimism; investors should weigh fundamental strengths against recent sentiment shifts.

02

Market read

The news is highly relevant for investors and traders focusing on the automotive parts sector and Dorman's stock.

03

What to watch

Potential macroeconomic headwinds or sector-specific challenges not discussed in the news could impact stock performance.

Timing: moderate; news is recent and relevant for upcoming trading sessions

Background

Dorman Products, Inc. is a key player in the automotive aftermarket parts industry, with a broad product portfolio and extensive distribution network.

Company-level read

Ticker impact

$DORMNeutralMedium confidence
Context

The news pertains directly to Dorman Products, Inc., a NASDAQ-listed company with a moderate buy consensus from brokerages.

Expected impact

Potential sideways movement with slight upward bias; short-term volatility may increase due to analyst sentiment shifts.

Evidence & confidence

The consensus rating and target suggest moderate positive outlook, but recent downgrades introduce uncertainty. Without current stock price and technical data, precise movement prediction remains cautious.

$DORMNeutralMedium confidence
Context

The news is highly relevant to Dorman Products, given the direct analyst ratings and market data.

Expected impact

Likely stability with potential for gradual increase; short-term volatility possible.

Evidence & confidence

The mixed analyst signals and lack of current price data limit definitive predictions. Long-term investors may find this favorable, while day traders should watch for volatility.

Market effects

The automotive parts sector may experience slight positive sentiment due to analyst optimism for Dorman Products.

Limited regional impact; company-specific news unlikely to influence broader regional markets.

Low; the news pertains to a U.S.-listed company with no immediate global market implications.

Counterpoint

Some analysts' downgrades may signal overhyped optimism; the stock could face downward correction.

Key entities

  • Dorman Products, Inc.

    A manufacturer and distributor of automotive replacement parts.

  • MarketBeat

    Provider of financial news and analyst ratings.

Related articles

$DORMMedAI 8/10

Dorman Products (DORM) Q2 2026 Earnings Call Transcript

Dorman Products (DORM) reported Q2 2026 net sales of $544.6 million (+0.7%) and adjusted diluted EPS of $3.08 (+50%), helped by a $1.18 per share IEEPA tariff refund. Adjusted gross margin rose to 46.1%. FY2026 guidance: net sales growth 3% to 5% and adjusted EPS $8.50 to $8.80.

$DORMMedAI 8/10

Dorman Products Q2 net sales rise to $544.6 million

Dorman Products reported Q2 2026 net sales of $544.6 million, up 0.7% from $541.0 million. Net income rose to $87.8 million and diluted EPS increased 53% to $2.93, aided by IEEPA tariff cost recovery, according to the company. Operating cash flow was $152.6 million; it repurchased $47 million of shares. Updated guidance: net sales growth 3% to 5% and EPS $7.93 to $8.23.

$DORMMed

Dorman Products, Inc. (DORM): Results of Operations and Financial Condition

Dorman Products, Inc. (DORM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dorman Products, Inc. Reports Second Quarter 2026 Results; Updates 2026 Guidance Highlights (All comparisons are to the prior year period unless otherwise noted) : • Net sales of $544.6 million for the quarter, up 0.7% • Diluted earnings per share (“EPS”) of $2.93, u

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.